Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

Biopharmaceutics and Drug Disposition

Volumn 36, Issue 3, 2015, Pages 148-162

  Nakamaru, Yoshinobu ^a,b   Emoto, Chie ^a   Shimizu, Makiko ^a   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

DPP 4 inhibitor; drug drug interaction; PBPK modeling; teneligliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; KETOCONAZOLE; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GROUPS BY AGE; HUMAN; INTRINSIC CLEARANCE; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SENSITIVITY ANALYSIS; VOLUME OF DISTRIBUTION; ADULT; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; INTESTINE; KIDNEY FAILURE; LIVER; LIVER DISEASE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; YOUNG ADULT;

ADULT; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINES; KETOCONAZOLE; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRAZOLES; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; THIAZOLIDINES; YOUNG ADULT;

EID: 84926452844     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1928     Document Type: Article

References (12)

1. Huang SH, Abernethy DR, Wang Y, Zhao P, Zineh I,. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci 2013; 102: 2912-2923. doi: 10.1002/jps.23570.
2. Sinha V, Zhao P, Huang SM, Zineh I,. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Clin Pharmacol Ther 2014; 95: 478-480. doi: 10.1038/clpt.2014.46.
3. Eto T, Inoue S, Kadowaki T,. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1040-1046. doi: 10.1111/j.1463-1326.2012.01662.x.
4. Nakamaru Y, Hayashi Y, Ikegawa R, et al., Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014; 44: 242-253. doi: 10.3109/00498254.2013.816891.
5. Nakamaru Y, Hayashi Y, Sekine M, et al., Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. Clin Ther 2014; 36: 760-769. doi: 10.1016/j.clinthera.2014.03.002.
6. Halabi A, Maatouk H, Siegler KE, Faisst N, Lufft V, Klause N,. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Develop 2013; 2: 246-254.
7. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A,. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223. doi: 10.1517/17425250802691074.
8. Jamei M, Turner D, Yang J, et al., Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-237. doi: 10.1208/s12248-009-9099-y.
9. Harvey JN,. Trends in the prevalence of diabetic neuropathy in type 1 and type 2 diabetes. Curr Opin Nephron Hypertens 2003; 12: 317-322. doi: 10.1097/00041552-200305000-00015.
10. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN,. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002; 51: 236-243.
11. Cashman JR, Zhang J,. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos 2002; 30: 1043-1052.
12. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A,. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol 2011; 4: 261-274. doi: 10.1586/ecp.10.143.